Curative efficacy of benazepril combined with atorvastatin on plasma NT-proBNP and its efficacy in chronic cardiac failure
10.3969/j.issn.1005-1678.2017.01.057
- VernacularTitle:贝那普利联合阿托伐他汀对慢性心力衰竭患者的疗效及对血浆NT-proBNP的影响
- Author:
Ming HE
;
Lihui WANG
;
Jintao LIU
- Keywords:
benazepril;
atorvastatin;
combination;
chronic cardiac failure;
N-terminal pro-brain natriuretic peptide
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(1):194-196
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study curative efficacy of benazepril combined with atorvastatin on N-terminal pro-brain natriuretic peptide (NT-proBNP) and its efficacy in the treatment of chronic cardiac failure. Methods 90 patients of chronic heart failure were selected as research objects. The control group were treated with benazepril, while the observation group were treated with benazepril combined with atorvastatin, 45 cases in each group. Then before and after treatment of 6 months, the cardiac function of left ventricular end-diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left ventricular eject fraction (LVEF), C-reactionprotein (CRP), interleukin- 6 (IL-6, tumor necrosis factor α (TNF-α) and plasma NT-proBNP levels were compared between two groups, and the efficacy was observed. Results After treatment, LVEDD and LVESD in observation group were lower than those in control group, the LVEF was higher than that in control group(P<0.05). The CRP,IL-6 and TNF-αlevels in observation group were lower than those in control group(P<0.05). The plasma NT-proBNP level in observation group was significantly lower than that in control group(P<0.05). The total effective rate of observation group was statistically higher than that that in the control group 95.55%(43/45)vs. 77.77%(35/45)(P<0.05). Conclusion Benazepril combined with atorvastatin in the treatment of chronic heart failure is significant, can reduce plasma NT-proBNP levels, improve the inflammatory factor.
